IOVA - Latest News
Iovance Biotherapeutics, Inc. (IOVA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.52B. Beta to the broader market is 0.70.
The article list below shows the most recent IOVA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IOVA Headlines
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
fool.com - Jun 23, 2026
Amgen provides a stable, diversified revenue base of nearly $36. 7 billion with significant net income.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com - Jun 19, 2026
SAN CARLOS, Calif. , June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics: Commercial, Clinical And Regulatory Tailwinds
seekingalpha.com - Jun 17, 2026
IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC,
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
globenewswire.com - Jun 3, 2026
First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted ther
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
fool.com - Jun 2, 2026
Iovance Biotherapeutics has surged over the past year, but the stock is down by nearly 80% over the past five years. Past issues with dilution and di
How News Affects IOVA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IOVA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IOVA news questions
- What is the latest IOVA news headline?
- The most recent IOVA headline (Jun 23, 2026) is "Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IOVA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IOVA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IOVA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.